文献速递肿瘤 PET/CT骨显像与常规 SPECT放射性药物与辐射防护

RGD类SPECT与PET显像剂在非肿瘤领域的应用

Non-oncological applications of RGD-based single-photon emission tomography and positron emission tomography agents.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-09-12

本文综述了RGD(精氨酸-甘氨酸-天冬氨酸)序列类显像剂在非肿瘤适应症中的SPECT与PET应用,聚焦2009至2020年文献。文章指出此类探针在克罗恩病或骨质疏松等缺乏获批显像剂的疾病监测中具有超说明书使用潜力,且其安全性已在多种临床评估中得到较广泛验证,非肿瘤临床转化可行性高。

要点

  • RGD序列可识别整合素等黏附蛋白,用于监测良性或病理性的细胞-基质相互作用。
  • 非肿瘤应用集中于2009–2020年文献,如克罗恩病、骨质疏松等疾病监测。
  • RGD类放射性药物安全性已在多种临床评估中较广泛检验,支持非肿瘤转化。

核心结论

  • RGD类放射性药物及其他显像剂在非肿瘤领域的临床转化可行性高,无需经历耗时的广泛开发流程。

研究设计与样本

  • 本文为综述,聚焦2009至2020年关于RGD类显像剂非肿瘤应用的SPECT与PET文献。

主要发现

  • 基础研究已阐明整合素参与多种非肿瘤疾病。
  • RGD类放射性药物在多种性质的临床评估中已较广泛评价安全性。
  • 非肿瘤应用相对肿瘤应用仍未被充分利用。

关键数值与推荐

  • RGD为Arg-Gly-Asp序列,是多种黏附性细胞外基质与细胞表面蛋白的结合基序。
  • 作者提出RGD显像剂可用于克罗恩病或骨质疏松等无获批显像剂疾病的超说明书监测。

临床怎么用

  • 在缺乏获批显像剂的非肿瘤疾病(如克罗恩病、骨质疏松)中,可考虑超说明书使用RGD类SPECT/PET探针进行疾病监测。

局限性

  • 本文为综述,非原始研究,未提供新的样本量、阈值或疗效数据。
  • 非肿瘤应用仍相对未被充分开发,相关临床证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Non-invasive imaging techniques (especially single-photon emission tomography and positron emission tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. METHODS AND SCOPE: This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-photon emission tomography and positron emission tomography). The focus is on the last 10 years of scientific literature (2009-2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn's disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. CONCLUSION: Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausible. Graphical abstract.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ebenhan T, Kleynhans J, Zeevaart JR, et al. Non-oncological applications of RGD-based single-photon emission tomography and positron emission tomography agents. Eur J Nucl Med Mol Imaging. 2020. PMID: 32918574. doi:10.1007/s00259-020-04975-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。